Greenland Mines Ltd (NASDAQ: GRML) has announced that IP Australia has granted Australian Patent No. 2023252508, covering gene therapy technology exclusively licensed by the company’s Biotech Division. The patent pertains to the expression of the human Klotho protein for the treatment of neuromuscular diseases, including amyotrophic lateral sclerosis (ALS).
According to the company, the patent strengthens the intellectual property supporting its Klotho-based therapeutic platform. It includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. This development further supports the advancement of Greenland Mines’ KLTO-202 program, which is targeting ALS and other neuromuscular disorders.
The patent grant represents a milestone for the company’s biotech division, which is focused on developing therapies based on the Klotho protein. Klotho is known for its potential roles in aging and neuroprotection, and its expression is being explored as a therapeutic approach for neurodegenerative conditions. The KLTO-202 program aims to leverage this patented technology to create treatments that could slow or halt disease progression in ALS patients.
For leaders in the biotech and pharmaceutical industries, the strengthening of Greenland Mines’ patent portfolio signals a more competitive position in the gene therapy space. The claims covering delivery systems—both viral and non-viral—suggest the company is building a versatile platform that could be applied to multiple neuromuscular diseases beyond ALS. This could attract partnerships or licensing opportunities, as gene therapy remains a high-growth area in biotechnology.
The Australian patent is part of a broader strategy by Greenland Mines to build a multi-asset platform. The company has two operating divisions: Mining, focused on the Skaergaard Project in Greenland and the Sarfartoq rare earths project, and Biotech, which includes the Klotho-based KLTO-202 program. The company’s strategy centers on exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities, while advancing its North Atlantic Critical Metals Corridor vision.
For patients and healthcare providers, the patent progress offers hope for new treatment options. ALS is a devastating neurodegenerative disease with limited therapeutic options, and gene therapy approaches like those being developed by Greenland Mines could address underlying mechanisms of the disease. However, it is important to note that the technology is still in development, and clinical trials will be necessary to demonstrate safety and efficacy.
The broader impact on the biotech industry includes increased attention on Klotho as a therapeutic target. As more patents are granted, other companies may seek to develop competing or complementary technologies. The patent also provides Greenland Mines with a defensive position against potential infringement, which is critical for securing funding and partnerships.
Investors can find the latest news and updates relating to GRML in the company’s newsroom at https:/nnw.fm/GRML. The full press release is available at https://nnw.fm/PVbbH.
